Odd Lots D.A. Wallach Explains Why Biotech VC Is So Different
99 snips
Dec 12, 2025 
D.A. Wallach, co-founder of Time BioVentures and former lead singer of Chester French, shares his unique journey from music to biotech investing. He discusses the complexities of biotech, comparing it to a 'bag of options' with long timelines. Wallach emphasizes the importance of experienced founders and the challenges of clinical trials as major bottlenecks. He also tackles the impact of AI on drug discovery, the rise of China's biotech sector, and the nuances of patient autonomy, all while hinting at how music and biotech intersect.
AI Snips
Chapters
Transcript
Episode notes
Experience Matters More Than Youth
- Biotech values experience and 'gray hair' because clinical programs are expensive and irreversible.
- The sector prizes repeat operators who survived failures over youthful pivots.
Contract Research Opened Biotech Startups
- Infrastructure (CROs, contract research) lowered startup costs similar to cloud in tech.
- That spawned younger founders and 'tech‑bio' entrants but didn't erase domain expertise needs.
Don’t Confuse Discovery With Approval
- Recognize AI likely increases candidates entering the discovery funnel but won't remove clinical trial bottlenecks.
- Prioritize solutions that address expensive human trials, not only discovery volume.